Presented at American Society of Hematology annual meeting.

Celgene: Initial trial meets main endpoint in patients newly identified as having multiple myeloma Initial phase III trial results, presented at American Society of Hematology annual meeting, show 28 percent reduction in risk of progression and 22 percent decrease in threat of death Celgene today declared that data from the FIRST trial was offered on Sunday 8 December, during the Plenary Scientific Program at the 55th American Society Hematology annual meeting in New Orleans. Initial a stage III, multi-centre research in patients newly identified as having multiple myeloma and ineligible for stem cell transplant, included 72 sufferers from the UK .00006).


The stem cells by itself have the potential to safeguard damaged electric motor neurons in ALS. This potential increases when combined with additional known effects of GDNF. Previously, providing GDNF to the mind or spinal cord has been nearly impossible because it will not cross from the blood to the cells of the spinal cord. ‘We’re looking at a novel and exciting method of using stem cells as ‘Trojan horses’ that arrive at the sick engine neurons and delivers the protein wherever it’s required,’ Clive Svendsen, PhD, director of the Regenerative Medicine innovator and Institute of the project,. ‘Our early study indicates this approach offers significant potential and we’re excited to bring this treatment a step closer to helping ALS individuals.’ Related StoriesNYSCF, CBR collaborate to customize creation of high-quality stem cell linesPublic plan needed to decrease stem cell tourism, state expertsKey protein controls stem cell properties that could make them useful in regenerative medicineAbout 30,000 individuals in the United States have ALS, which affects nerve cells in the brain and the spinal-cord.